Intranasal Delivery of Emergency Epinephrine Takes Another Step Toward Realization
Concerning anaphylaxis emergencies and epinephrine, imagine if an "Epi nasal spray" became a viable treatment option instead of an intermuscular EAI injection device. It might happen sooner that you might think; new devices are being developed that don't require using a needle. And some of them do look very promising.
Intranasal Delivery of Emergency Epinephrine Takes Another Step Toward Realization

By Dave Bloom
2021/07/07
We’ve been following the progress of ARS Pharma’s and Bryn Pharma’s intranasal emergency epinephrine devices as they make their way through clinical trials. These devices are meant to provide a needle-free alternative to today’s auto-injectors for the treatment of anaphylaxis.
Now, yet another company is reporting promising results in the race to bring an intranasal device to market, although this one does so differently.
Nasus Pharma based in Tel Aviv is reporting positive results from a pilot study of their FMXIN002 candidate. Unlike the other devices, this device stores and delivers epinephrine in powder form.
According to Nasus, the pilot study is the first human study of powder epinephrine and provides additional compelling evidence to the robustness of their intranasal powder technology in addition to the recently published results of their intranasal naloxone study.